Ocata Therapeutics Inc fka OCAT

[Dragon Lady]

The Street.com, says SELL on Ocat. The Street.com aka "Cramers" site, aka Cramer of CNBC.

Well, there's probably IMO the first it looks like, much talked about, "coverage" and "visibility" that would come via being on the Nasdaq now.

http://www.thestreet.com/quote/OCAT.html

It says "SELL recommendation" on OCAT:

Quote-

"The Street's Analysis is Quantitative-driven / Fundamental Analysis. Here's the report:

RECOMMENDATION
We rate OCATA THERAPEUTICS INC (OCAT) a SELL. This is based on the dominance of unfavorable investment measures, which should drive this stock to significantly underperform the majority of stocks that we rate. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and feeble growth in its earnings per share.
HIGHLIGHTS
Net operating cash flow has decreased to -$5.99 million or 21.55% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is
significantly lower. OCATA THERAPEUTICS INC's earnings have gone downhill when comparing its most recently reported quarter with the same quarter a year earlier. This company has reported somewhat volatile earnings recently.
We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, OCATA THERAPEUTICS INC turned its bottom line around by earning $0.00 versus -$1.00 in the prior year. This year,
the market expects a decline in earnings from $0.00 to -$0.30.
The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income increased by 35.3% when compared to the same quarter one year prior, rising from -$5.75 million to -$3.72 million.
This stock has managed to decline in share value by 2.52% over the past twelve months. Regardless of the rise in share value over the previous year, we feel that the risks involved in investing in this stock do not
compensate for any future upside potential. The revenue fell significantly faster than the industry average of 36.4%. Since the same quarter one year prior, revenues slightly dropped by 2.5%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share."

Looks like OCAT is getting some "coverage" now like all Nasdaq stock typically do. "Coverage" can be good or bad I guess IMO -it cuts both ways.